Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis

杜皮鲁玛 医学 特应性皮炎 皮肤病科
作者
Margitta Worm,Eric L. Simpson,Diamant Thaçi,Robert Bissonnette,J.‐P. Lacour,Stefan Beissert,Makoto Kawashima,Carlos Ferrándiz,Catherine Smith,Lisa A. Beck,Kuo‐Chen Chan,Zhen Chen,Bolanle Akinlade,Thomas Hultsch,Heribert Staudinger,Abhijit Gadkari,Laurent Eckert,John D. Davis,Manoj Rajadhyaksha,Neil M.H. Graham
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:156 (2): 131-131 被引量:155
标识
DOI:10.1001/jamadermatol.2019.3617
摘要

The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD).To assess the efficacy and safety of different dupilumab regimens in maintaining response after 16 weeks of initial treatment.The Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (LIBERTY AD SOLO-CONTINUE) was a randomized, double-blind, phase 3 clinical trial conducted from March 25, 2015, to October 18, 2016, at 185 sites in North America, Europe, Asia, and Japan. Patients with moderate to severe AD who received dupilumab treatment and achieved an Investigator's Global Assessment score of 0 or 1 or 75% improvement in Eczema Area and Severity Index scores (EASI-75) at week 16 in 2 previous dupilumab monotherapy trials (LIBERTY AD SOLO 1 and 2) were rerandomized in SOLO-CONTINUE. After completing SOLO-CONTINUE, patients were followed up for up to 12 weeks or enrolled in an open-label extension. Data were analyzed from December 5 to 12, 2016.High-responding patients treated with dupilumab in SOLO were rerandomized 2:1:1:1 to continue their original regimen of dupilumab, 300 mg, weekly or every 2 weeks or to receive dupilumab, 300 mg, every 4 or 8 weeks or placebo for 36 weeks.Percentage change in EASI score from baseline during the SOLO-CONTINUE trial, percentage of patients with EASI-75 at week 36, and safety.Among the 422 patients (mean [SD] age, 38.2 [14.5] years; 227 [53.8%] male), continuing dupilumab treatment once weekly or every 2 weeks maintained optimal efficacy, with negligible change in percent EASI improvement from SOLO 1 and 2 baseline during the SOLO-CONTINUE trial (-0.06%; P < .001 vs placebo); percent change with the other regimens dose-dependently worsened (dupilumab every 4 weeks, -3.84%; dupilumab every 8 weeks, -6.84%; placebo, -21.67%). More patients taking dupilumab weekly or every 2 weeks (116 of 162 [71.6%]; P < .001 vs placebo) maintained EASI-75 response than those taking dupilumab every 4 weeks (49 of 84 [58.3%]) or every 8 weeks (45 of 82 [54.9%]) or those taking placebo (24 of 79 [30.4%]). Overall adverse event incidences were 70.7% in the weekly or every 2 weeks group, 73.6% in the every 4 weeks group, 75.0% in the every 8 weeks group, and 81.7% in the placebo group. Treatment groups had similar conjunctivitis rates. Treatment-emergent antidrug antibody incidence was lower with more frequent dupilumab dose regimens (11.3% in the placebo group and 11.7%, 6.0%, 4.3%, and 1.2% in the dupilumab every 8 weeks, every 4 weeks, every 2 weeks, and weekly groups, respectively).In this trial, continued response over time was most consistently maintained with dupilumab administered weekly or every 2 weeks. Longer dosage intervals and placebo resulted in a diminution of response for both continuous and categorical end points. No new safety signals were observed. The approved regimen of 300 mg of dupilumab every 2 weeks is recommended for long-term treatment.ClinicalTrials.gov identifier: NCT02395133.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
serina完成签到 ,获得积分10
1秒前
1秒前
xun完成签到 ,获得积分10
1秒前
明理的寒云完成签到,获得积分10
1秒前
song完成签到,获得积分10
2秒前
火星上勒发布了新的文献求助10
2秒前
jjdgangan完成签到,获得积分10
2秒前
2秒前
Owen应助renwoxing采纳,获得10
3秒前
123完成签到,获得积分10
3秒前
4秒前
迷你的冰巧完成签到,获得积分10
4秒前
Hello应助科研通管家采纳,获得10
4秒前
MchemG应助水濑心源采纳,获得10
4秒前
4秒前
4秒前
4秒前
4秒前
wzt完成签到,获得积分10
5秒前
咖啡博士完成签到 ,获得积分10
6秒前
幸运星完成签到 ,获得积分10
6秒前
莫愁完成签到,获得积分10
6秒前
科研牛马完成签到,获得积分10
6秒前
六氟合铂酸氙完成签到 ,获得积分10
6秒前
Promise发布了新的文献求助10
7秒前
jiangcai完成签到,获得积分10
9秒前
科研牛马发布了新的文献求助10
10秒前
汪洋发布了新的文献求助10
10秒前
11秒前
活力数据线完成签到,获得积分10
11秒前
刘k完成签到,获得积分10
11秒前
JXDYYZK完成签到,获得积分10
12秒前
老八的嘴完成签到,获得积分20
12秒前
自信以冬完成签到,获得积分10
12秒前
12秒前
SciGPT应助DCOI采纳,获得10
13秒前
13秒前
愉快乐瑶完成签到,获得积分10
14秒前
sure完成签到 ,获得积分10
14秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968603
求助须知:如何正确求助?哪些是违规求助? 3513420
关于积分的说明 11168029
捐赠科研通 3248900
什么是DOI,文献DOI怎么找? 1794540
邀请新用户注册赠送积分活动 875187
科研通“疑难数据库(出版商)”最低求助积分说明 804676